Clinical Trial

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-09-21; most recent amendment 2026-07-20.
Trial Details
NCT Number NCT06057935
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Malignant Peritoneal Mesothelioma, Peritoneal Mesothelioma, Mesothelioma, Mesothelioma, Malignant, Malignant Mesothelioma
Enrollment 64 participants
Start Date 2023-09-21
Primary Completion 2028-09-21 (estimated)
Study Completion 2028-09-21 (estimated)
Updated on ClinicalTrials.gov 2026-07-21